Physician profile
James E Gutmann
NPI 1790851897
$693.00
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $124.57 | 2019-2020 | |
| Novo Nordisk INC | $66.78 | 2019 | |
| Abbott Laboratories | $66.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.23 | 2019-2020 | |
| Lilly USA, LLC | $57.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.14 | 2019-2020 | |
| Pfizer INC. | $30.87 | 2019-2020 | |
| Amgen INC. | $26.70 | 2019 | |
| Genentech USA, INC. | $24.59 | 2019 | |
| Merck Sharp & Dohme LLC | $23.67 | 2019 | |
| Amarin Pharma, INC. | $23.04 | 2019-2020 | |
| Horizon Therapeutics Plc | $20.07 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.23 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.22 | 2020 | |
| Astellas Pharma US INC | $12.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.96 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gutmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.